Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, announced today that the Carragelose-based nasal spray has been out-licensed for the South Korean market. Marinomed’s exclusive license partner is stock-listed Hanmi Pharmaceutical Co., Ltd (128940:Korea SE), headquartered in Seoul. Hanmi Pharmaceutical is one of the leading pharmaceutical South Korean companies with a broad product portfolio in many therapeutic areas and a strong marketing expertise. Under the agreement, Hanmi is responsible for pursuing local approval for the Carragelose nasal spray and will market and distribute the product in South Korea.
“We are delighted to enter into another licence agreement with a strong partner for the marketing of our Carragelose nasal spray in South Korea. With Hanmi Pharmaceutical, we are once more expanding the global presence of our virus-blocker,” said Dr. Andreas Grassauer, CEO of Marinomed. “This partnership brings us closer to our goal of making Carragelose accessible to everyone. Carragelose has clinically proven to be safe and highly efficacious in preventing and treating viral respiratory diseases, including COVID-19.”
The full press release is available as download here: